Larimar Therapeutics, Inc.
LRMR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001374690
In the last 90 days, Larimar Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 163 institutions reported holding it in 13F filings for Q2 2026, worth $292.7M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $166.9K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 163
- 13F valueReported value at the end of Q2 2026
- $292.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LRMR, Q2 2026
No superinvestor reported holding LRMR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Larimar Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2026 (view filing)4:05 PM ET | Jul 6 | 2 days | Hamilton Thomas EdwardDirector | PPurchase | +50.0K | $3.34 | +$166.9K | +7.5%714.8K after | |
| Mar 2, 2026 (view filing)7:46 PM ET | Feb 27 | 3 days | Deerfield Management Company, L.P. and 9 othersDirector, 10% Owner, Other: * Director by Deputization | PPurchase | +5.00M | $5.00 | +$25.0M | +413.9%6.21M after | 4 lots |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Hamilton Thomas EdwardDirector | PPurchase | +100.0K | $5.00 | +$500.0K | +17.7%664.8K after | |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Thomas Frank EDirector | PPurchase | +5.00K | $5.00 | +$25.0K | +250.0%7.00K after | |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Sherman Jeffrey WDirector | PPurchase | +5.00K | $5.00 | +$25.0K | New position5.00K after | |
| Aug 4, 2025 (view filing)6:28 PM ET | Jul 31 | 4 days | Deerfield Management Company, L.P. and 9 othersDirector, 10% Owner, Other: * Director by Deputization | PPurchase | +9.38M | $3.20 | +$30.0M | New position7.32M after | 3 lots |
| May 31, 2024 (view filing) | Feb 16 | 105 daysLate | Hamilton Thomas EdwardDirector | PPurchase | +57.2K | $8.74 | +$500.0K | +11.3%564.8K after | |
| Feb 16, 2024 (view filing)2:37 PM ET | Feb 16 | Same day | Deerfield Management Company, L.P. and 9 othersDirector, 10% Owner, Other: * Director by Deputization | PPurchase | +4.29M | $8.74 | +$37.5M | New position4.21M after | 3 lots |
| Feb 15, 2024 (view filing) | Feb 14 | 1 day | Thomas Frank EDirector | PPurchase | +2.00K | $11.00 | +$22.0K | New position2.00K after | |
| Dec 8, 2023 (view filing) | Dec 7 | 1 day | Shankar GopiChief Development Officer | PPurchase | +5.00K | $3.73 | +$18.6K | New position5.00K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Larimar Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 35,606,974 | $108.6M | 1.13% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 9,163,157 | $27.9M | 4.25% | +2,043,150+28.7% | Added |
| BlackRock, Inc. | 5,678,035 | $17.3M | 0.00% | +1,925,835+51.3% | Added |
| Defilade Capital Management, L.P. | 3,670,135 | $11.2M | 1.50% | +3,670,135 | New |
| Driehaus Capital Management LLC | 3,163,423 | $9.65M | 0.06% | +229,024+7.8% | Added |
| Vanguard Capital Management LLC | 2,974,901 | $9.07M | 0.00% | +108,552+3.8% | Added |
| RTW Investments, LP | 2,565,999 | $7.83M | 0.07% | +1,065,999+71.1% | Added |
| AQR Capital Management LLC | 2,371,414 | $7.23M | 0.00% | +1,553,897+190.1% | Added |
| Marshall Wace, LLP | 2,012,458 | $6.14M | 0.01% | +1,078,994+115.6% | Added |
| DAFNA Capital Management LLC | 2,008,164 | $6.12M | 1.17% | −21,000−1.0% | Reduced |